The most interesting article in this week's reading was on the preoperative treatment of breast cancer. L Cary et al (JCO Vol 34, No 6 Feb 20, 2016 p 542) report on 305 patients with Her-2/neu over-expressing breast cancers who received chemotherapy with trastuzumab, lapatinib or both for 16-weeks and were then taken to the operating room. The authors observed significant differences in response rates that were (partially) explained by genetic differences between the cancers. These genetic differences give some insights into who is most likely to benefit from our current standard breast cancer treatments. To read more about this study, click on this link: Full review